Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: Selective localization of IgG from cerebrospinal fluid to brain parenchyma

Fig. 3

NMOSD-like pathology at the needle insertion. a, b Representative sagittal brain sections from mice intrathecally injected with NMO-IgG and complement, NMO-IgG alone, or normal-IgG with complement 1 day post needle insertion. a Micrograph showing IgG deposition in and around the needle track 1 day after intrathecal injection. b Low-level deposition of IgG away from the needle track 1 day after intrathecal injection. c, d Representative sagittal brain sections from mice intrathecally injected with NMO-IgG and complement, NMO-IgG alone, or normal-IgG and complement 1 day post needle insertion. c Micrograph showing IgG deposition in and around the needle track 3 days after intrathecal injection. d Lack of low-level deposition of IgG away from the needle track 3 days after intrathecal injection. e NMO-like pathology in mice 3 days after intrathecal injection. Mice received NMO-IgG and complement by intrathecal injection 1 day post needle insertion. Pathology was identified by loss of AQP4 and GFAP staining (brown) together with deposition of IgG and activated complement (C9neo) (brown). Bars 200 μm (a, c), 100 μm (e), and 50 μm (b, d)

Back to article page